4.4 Article

A generic platform for the immobilisation of engineered biocatalysts

期刊

TETRAHEDRON
卷 75, 期 3, 页码 327-334

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tet.2018.12.004

关键词

Biocatalysis; Immobilisation; Controlled-pore glass; Engineered enzymes

资金

  1. European Union [613849]
  2. BBSRC from the UK Biotechnology and Biological Sciences Research Council [BB/K00199X/1, BB/M006832/1]
  3. Centre of Excellence for Biocatalysis, Biotransformations and Biomanufacture (CoEBio3)
  4. ERC [742987]
  5. BBSRC [BB/K00199X/1, BB/M006611/1, BB/M006832/1] Funding Source: UKRI
  6. EPSRC [EP/S01778X/1] Funding Source: UKRI

向作者/读者索取更多资源

The application of biocatalysis in the pharmaceutical industry is rapidly growing as a result of increased access to enzymes that meet the demands of industrial processes. This expansion of activity has led to a corresponding increase in the demand for immobilised enzymes. EziG (TM) (EnginZyme AB, Sweden) is marketed as a general matrix for enzyme immobilisation on controlled porosity glass. In this work we identified criteria for a general enzyme immobilisation technology in the context of the requirements of the pharmaceutical industry. We subsequently evaluated EziG (TM) for generality in a series of case studies for the application of immobilised biocatalysts. In this study we have focussed on the challenges facing both academic and industrial applications such as enzyme stability, multistep reactions and reactions in continuous flow. (C) 2018 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据